Evidence map›Paper›PMID 33034276›Full record

ArticleTechnology in cancer research & treatment

Clinical Outcomes and Predictors in Patients With Unresectable Colorectal Cancer Liver Metastases Following Salvage Percutaneous Radiofrequency Ablation: A Single Center Preliminary Experience.

Ying Wang, Guang-Yuan Zhang, Li-Chao Xu, Xin-Hong He, Hao-Zhe Huang, Guo-Dong Li, Yao-Hui Wang, Guang-Zhi Wang, Wen-Tao Li

Abstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ying WangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.ORCID 0000-0002-0838-4366
Guang-Yuan ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.
Li-Chao XuDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.
Xin-Hong HeDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.
Hao-Zhe HuangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.
Guo-Dong LiDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.
Yao-Hui WangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.
Guang-Zhi WangDepartment of Medical Imaging Center, Affiliated Hospital, Weifang Medical University, Shandong, China.
Wen-Tao LiDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Xuhui, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to investigate the clinical efficacy of salvage percutaneous radiofrequency ablation in patients with unresectable colorectal cancer liver metastases.

methodsThe cohort consisted of 81 patients with 126 colorectal cancer liver metastases who underwent radiofrequency ablation between January 2012 and September 2016. The clinical data and ablation data were retrospectively analyzed. The local tumor progression-free survival, overall survival, and prognostic factors were analyzed using the log-rank test and Cox regression model.

resultsThe technique success rate was 99.21%. The primary efficacy rate was 100% at the 1-month follow-up. Minor complications were observed in 2 patients, which recovered within 1 week. The median local tumor progression-free survival time of all patients was 29.8 months. The absence of subsequent chemotherapy was an independent predictor of a shorter local tumor progression-free survival time (

conclusionsPercutaneous radiofrequency ablation is safe in patients with colorectal cancer liver metastases refractory from chemotherapy. Subsequent chemotherapy is important to enhance local control. Small lesions and favorable early responses are related to prolonged overall survival.

Indexed as

AdultAgedAged, 80 and overCatheter AblationColorectal NeoplasmsFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalProgression-Free SurvivalProportional Hazards ModelsRadiofrequency AblationSalvage Therapycolorectal cancer liver metastaseslocal tumor progressionoverall survivalpredictorradiofrequency ablationunresectable

Identifiers

PMID33034276
PMCPMC7549072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.